stockportfolio.pro
NovoCure Limited (NVCR)
Healthcare · Medical Devices · NasdaqGS
NovoCure Limited revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.89M | $177.03M | $248.07M | $351.32M | $494.37M | $535.03M | $537.84M | $509.34M | $605.22M | $655.35M |
| Gross profit | $36.61M | $121.42M | $168.02M | $262.71M | $387.87M | $420.15M | $422.97M | $381.06M | $468.04M | $488.47M |
| Net income | $-131.84M | $-61.66M | $-63.56M | $-7.23M | $19.81M | $-58.35M | $-92.53M | $-207.04M | $-168.63M | $-136.23M |
| Net margin | -159.1% | -34.8% | -25.6% | -2.1% | 4.0% | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
Source: NovoCure Limited SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of NovoCure Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NVCR in your portfolio →
NovoCure Limited financial history by metric
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NovoCure Limited — frequently asked questions
What is NovoCure Limited's revenue?
NovoCure Limited (NVCR) reported revenue of $655.35M for fiscal year 2025, up 8.3% from the prior year, according to its SEC filings.
Is NovoCure Limited profitable?
No — NVCR reported a net loss of $-136.23M in fiscal 2025.
What is NVCR's P/E ratio?
NovoCure Limited trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is NovoCure Limited growing?
NVCR's revenue grew at roughly 5.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does NovoCure Limited have?
As of fiscal year 2025, NVCR carried roughly $195.05M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is NovoCure Limited's gross margin?
NVCR's gross margin was 74.5% in fiscal 2025 — gross profit of $488.47M on revenue of $655.35M.
What is NovoCure Limited's market cap?
NovoCure Limited (NVCR) has a market capitalization of about $1.95B, based on the latest data in our nightly-refreshed cache.
When does NovoCure Limited's fiscal year end?
NVCR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from NovoCure Limited's official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.